Credit rating agency, ICRA has assigned ‘A1+’ rating to Lupin’s short-term credit facilities of Rs 1310 crore. The rating agency has also assigned ‘AA+’ rating to the company’s long-term credit facilities worth Rs 190 crore. Moreover, the rating agency has assigned ‘AA+’ rating to the company’s Non-Convertible Debenture (NCD) programme worth Rs 100 crore.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.